Is Temsirolimus on the market?

Temsirolimus (Temsirolimus) is manufactured by Wyeth Pharmaceuticals (Wyeth Pharmaceuticals) developed under the trade name Torisel, was approved by the US Food and Drug Administration (FDA) in May 2007, and was approved by the European Medicines Agency (EMA) in November of the same year, and contains the active substancetemsirolimus.

Temsirolimus is a drug used to treat people with certain types of cancer, including advanced renal cell carcinoma (a type of kidney cancer), which means the cancer has started to spread; and mantle cell lymphoma (a cancer of B cells, a type of white blood cell), which is used mainly in adult patients when the lymphoma has come back after previous treatment or if other treatments haven't worked. These diseases are rare, and temsirolimus was designated on various dates as an "orphan drug" (a drug for a rare disease). The drug is only available by prescription, so patients must use it under the supervision of a doctor experienced with cancer drugs.

The original drug temsirolimus has not yet been marketed in China, and therefore cannot be included in domestic medical insurance. The original temsirolimus drug marketed overseas has a Turkish version and a European version. The ingredients of the two are basically the same. The price of each box of 30mg/1.2mL may be more than 10,000 yuan, and the price of 25mg/mL may be around 3,000 yuan per box (the price may fluctuate due to exchange rates). There is currently no generic version of temsirolimus available on the market. For more drug information and specific prices, please consult a medical consultant.